Alzamend Neuro, Inc.
PublicBiotech · Atlanta, GA
Financials
FY2015–FY2026 · from SEC filings · hover any figure for its sourceChart shows the most recent 8 fiscal years; 4 earlier years are in the table below.
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inDotted grey bars are our estimate for rounds that didn't state one: the round's share price × the shares outstanding in its filings. Same measure as blue, but rougher.
Cap table
Share counts as of Jan 31, 2025| Class | Outstanding | Votes / share | Share of total | Last price |
|---|---|---|---|---|
| Preferred Stockpreferred | 2,100 | — | 0.04% | — |
| Common stock | 5,796,834 | 1 | 100.0% | $1.50Nov 2019 |
| Total | 5,798,934 | 100% |
Shares outstanding over timein today's share terms
Changes in named holdersshares in today's terms · % of all shares at the time
- Henry Nisser182K (12.2%) Nov 2019 → 417K (0.63%) Aug 2020
- Kenneth S. Cragun375K (25.0%) Nov 2019 → 625K (0.94%) Aug 2020
- Stephan Jackman813K (54.2%) Nov 2019 → 1.3M (1.98%) Aug 2020
Principal holders% as the filing states it, Aug 28, 2020
- Milton C. Ault, III55,000,000 Common Stock50.6%of
- Ault Life Sciences, Inc.37,500,000 Common Stock37.0%of
- Ault Life Sciences Fund, LLC15,000,000 Common Stock21.8%of
- Philip E. Mansour2,500,000 Common Stock3.77%of
- William B. Horne2,500,000 Common Stock3.77%of
- Stephan Jackman1,312,500 Common Stock2.02%of
- Kenneth S. Cragun625,000 Common Stock0.97%of
- Henry Nisser416,667 Common Stock0.65%of
From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.
Fundraising history
Team
6 peopleNames and titles as disclosed on SEC Form 1-A. Bios and photos come from the platform campaign page and may be out of date.
SEC filings
View all 52 filings on EDGAR- Form 10-QSep 10, 20260001214659-26-011572EDGAR
- Form 10-KJul 22, 20260001214659-26-008832EDGAR
- Form 10-QMar 11, 20260001214659-26-003166EDGAR
- Form 10-QDec 9, 20250001214659-25-017793EDGAR
- Form 10-QSep 10, 20250001214659-25-013609EDGAR
- Form 10-KJul 22, 20250001214659-25-010763EDGAR
- Form 10-QMar 10, 20250001214659-25-004123EDGAR
- Form 10-QDec 11, 20240001214659-24-020264EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.